IJESD • International Scientific Journal
ISSN: 2955-0386
IF: 12.31

SYSTEMIC SCLEROSIS (SCLERODERMA) COMPREHENSIVE ANALYSIS OF PATHOPHYSIOLOGY, CLINICAL SUBTYPES, DIAGNOSTIC ADVANCES, AND THERAPEUTIC HORIZONS

Tashkent State Medical University
Hilola To‘xtasinovna Mirakhmedova,
Baxtigul Ilkhomiddinovna Abdakimova

Abstract

Systemic sclerosis (SSc, commonly known as scleroderma) is a heterogeneous, multisystem autoimmune disease characterized by a triad of severe vascular dysfunction, immune dysregulation with specific autoantibody production, and widespread progressive tissue fibrosis. SSc exhibits the highest individual case fatality rate among all systemic autoimmune rheumatic diseases. This review provides a comprehensive synthesis of current scientific understanding regarding SSc. We explore the pathophysiological signaling cascades involving transforming growth factor-beta (TGF-β), endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF). Furthermore, we detail clinical subtypes—limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc)—alongside major organ complications including interstitial lung disease (SSc-ILD), pulmonary arterial hypertension (PAH), and scleroderma renal crisis (SRC). Advances in nailfold videocapillaroscopy and autoantibody profiling are examined, followed by an evaluation of emerging therapeutic modalities, including targeted biological agents, anti-fibrotic therapies, and autologous hematopoietic stem cell transplantation (aHSCT).

Keywords: Systemic Sclerosis, Scleroderma, Fibrosis, Vasculopathy, Interstitial Lung Disease, Anti-Scl-70, Nintedanib.

1. Introduction & Epidemiological Profile

Systemic sclerosis (SSc) is an intricate autoimmune connective tissue disorder characterized by excessive extracellular matrix (ECM) accumulation, widespread microvascular alteration, and profound immunological abnormalities **Denton & Khanna (2017)**. The disease presents a broad clinical spectrum ranging from localized skin involvement (morphoea) to fatal systemic involvement affecting the skin, lungs, gastrointestinal tract, myocardium, and kidneys. Epidemiological studies indicate an incidence ranging between 8 to 56 new cases per million persons annually, with an estimated prevalence of 50 to 300 cases per million worldwide **Allanore et al. (2015)**. SSc demonstrates a marked female-to-male preponderance ranging from 4:1 to 8:1, typically manifesting between the fourth and sixth decades of life.

Despite recent diagnostic advances, SSc carries a significant mortality burden. Morbidity is driven primarily by internal organ complications, notably SSc-associated interstitial lung disease (SSc-ILD) and pulmonary arterial hypertension (PAH), which have superseded scleroderma renal crisis (SRC) as the leading causes of SSc-related death following the introduction of angiotensin-converting enzyme (ACE) inhibitors **Khanna et al. (2020)**.

2. Pathophysiology and Etiopathogenesis

The pathogenesis of SSc involves a complex interplay among three distinct pathological pillars: early microvascular injury, innate and adaptive immune cell activation, and irreversible fibroblast hyperactivation resulting in connective tissue fibrosis.

2.1 Vascular Endothelial Injury & Microvasculopathy

Microvascular endothelial destruction is widely recognized as the earliest initiating event in SSc. Environmental triggers, infection, or oxidative stress induce endothelial cell apoptosis and upregulation of cell adhesion molecules (E-selectin, ICAM-1). Impaired production of vasodilators such as nitric oxide (NO) and prostacyclin occurs in parallel with overexpression of potent vasoconstrictors, predominantly Endothelin-1 (ET-1). Chronic vasospasm leads to hypoxia, chronic ischemia, and defective angiogenesis driven by deregulated Vascular Endothelial Growth Factor (VEGF) signaling. Over time, capillary loss (rarefaction) and luminal obliterative arterial remodeling ensue, manifesting clinically as Raynaud's phenomenon and digital ulcers.

2.2 Immune Activation and Autoimmunity

Both innate immune components (plasmacytoid dendritic cells, macrophages, mast cells) and adaptive immune cells (T-helper 2 [Th2] cells, B lymphocytes) participate in disease propagation. Th2 cell polarization leads to elevated secretion of pro-fibrotic cytokines, notably Interleukin-4 (IL-4), Interleukin-13 (IL-13), and Interleukin-6 (IL-6). B-cell hyperreactivity manifests through the generation of highly specific autoantibodies, including anti-topoisomerase I (anti-Scl-70), anti-centromere (ACA), and anti-RNA polymerase III. These autoantibodies contribute directly to tissue destruction and serve as essential diagnostic markers.

2.3 Fibroblast Activation and Extracellular Matrix Deposition

The culmination of vascular injury and immune signaling is the activation of quiescent tissue fibroblasts into contractile myofibroblasts expressing alpha-smooth muscle actin (α-SMA). Transforming Growth Factor-beta (TGF-β) serves as the primary master driver of fibrosis through Canonical SMAD2/3 and non-canonical signaling pathways. Activated myofibroblasts synthesize excessive Collagen Type I, Collagen Type III, and fibronectin. Additionally, mechanical stiffening of the extracellular matrix establishes a self-sustaining positive feedback loop, driving ongoing collagen cross-linking and permanent tissue scarring.

3. Clinical Subtypes and Organ Manifestations

Systemic sclerosis is classified into two main clinical subsets based on the extent and pattern of cutaneous involvement, as established by LeRoy et al.:

Feature	Limited Cutaneous SSc (lcSSc)	Diffuse Cutaneous SSc (dcSSc)
Skin Involvement	Distal to elbows/knees, face, and neck; slow progression	Distal and proximal limbs, trunk; rapid skin thickening
Raynaud's Phenomenon	Precedes skin involvement by years or decades	Onset concurrent with or shortly before skin changes
Predominant Autoantibody	Anti-Centromere Antibodies (ACA) (~60–70%)	Anti-Scl-70 (Anti-Topoisomerase I) (~30–40%)
Key Visceral Risk	Late-onset Isolated PAH, Severe Calcinosis, CREST	Early progressive SSc-ILD, Scleroderma Renal Crisis
Capillaroscopy Pattern	"Late" pattern develops slowly (giant loops, avascular zones)	Rapid transition to severe capillary loss and disorganization

3.1 Cardiopulmonary Complications

Interstitial lung disease (SSc-ILD) affects up to 60–70% of SSc patients, presenting pathologically as non-specific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP). High-Resolution Computed Tomography (HRCT) displays ground-glass opacities, reticulation, and

traction bronchiectasis. Pulmonary arterial hypertension (PAH) develops in 8–12% of patients and requires confirmation via right heart catheterization (mean pulmonary arterial pressure >20 mmHg at rest).

3.2 Renal & Gastrointestinal Involvement

Scleroderma Renal Crisis (SRC) occurs in 5–10% of dcSSc cases, presenting with acute onset malignant hypertension, rapidly progressive renal failure, and microangiopathic hemolytic anemia. Gastrointestinal involvement affects over 90% of patients across the entire gut, manifesting as esophageal dysmotility, severe gastroesophageal reflux disease (GERD), small intestinal bacterial overgrowth (SIBO), and intestinal pseudo-obstruction.

Diagnostic Criteria & Biomarker Profiling

The 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis improved diagnostic sensitivity, particularly for early disease detection **Van den Hoogen et al. (2013)**. A total score of ≥9 classifies an individual as having definite SSc. Key weighted criteria include skin thickening of the fingers extending proximal to the metacarpophalangeal joints (score 9), fingertip lesions (ulcers or pitting scars, 2–3 points), telangiectasia (2 points), abnormal nailfold capillaries (2 points), PAH/ILD (2 points), Raynaud's phenomenon (3 points), and SSc-specific autoantibodies (3 points).

Nailfold Videocapillaroscopy (NVC) represents a cornerstone non-invasive modality. Early NVC changes feature enlarged giant capillaries and microhemorrhages, progressing to active capillary loss, and culminating in severe avascular areas with neoangiogenic arborization in late stages.

Therapeutic Paradigms & Emerging Modalities

Management of SSc necessitates organ-specific targeted approaches combining immunomodulation, vasoactive therapy, and anti-fibrotic intervention:

Vasoactive Therapy: Dihydropyridine calcium channel blockers (nifedipine), phosphodiesterase-5 (PDE-5) inhibitors (sildenafil), and endothelin receptor antagonists (bosentan) are effective for Raynaud's and digital ulcer prevention. Intravenous iloprost is reserved for severe ischemic digital ulcers.

Immunomodulatory Strategies: Mycophenolate mofetil (MMF) and cyclophosphamide represent first-line disease-modifying agents for active dcSSc skin disease and SSc-ILD. Biological agents targeting IL-6 signaling (Tocilizumab) and B-cell depletion (Rituximab) have demonstrated efficacy in stabilizing pulmonary function and reducing skin thickness scores **Khanna et al. (2020)**.

Anti-Fibrotic Therapies: Nintedanib, a intracellular tyrosine kinase inhibitor targeting FGFR, VEGFR, and PDGFR, received FDA approval following the SENSCIS trial, demonstrating a significant reduction in the annual rate of decline in forced vital capacity (FVC) in SSc-ILD **Distler et al. (2019)**.

Autologous Hematopoietic Stem Cell Transplantation (aHSCT): In severe, rapidly progressive dcSSc with high risk of organ failure, randomized controlled trials (ASTIS, STATIS, SCOT) have shown that aHSCT offers superior long-term overall and event-free survival compared to conventional cyclophosphamide pulse therapy **Volkmann et al. (2022)**.

References

1. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. *Nat Rev Dis Primers*. 2015;1:15002.

2. Denton CP, Khanna D. Systemic sclerosis. *Lancet*. 2017;390(10103):1685-1699.

3. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *N Engl J Med*. 2019;380(26):2518-2528.

4. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2020;8(10):963-974.

5. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis*. 2013;72(11):1747-1755.

6. Volkmann ER, Tashkin DP, Sim M, et al. Short- and long-term outcomes of immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease. *Arthritis Rheumatol*. 2022;74(7):1210-1219.